Navigation Links
Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
Date:4/28/2010

SAN FRANCISCO, April 28 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical-stage cancer biotherapeutics company, today expanded its board of directors with the appointment of Paul B. Cleveland, executive vice president of corporate development and chief financial officer of Affymax, Inc.  

"With JX-594 entering Phase 3 trials for the treatment of liver cancer by the end of this year and a strong pipeline of novel clinical-stage products behind it, we believe Paul's superior financial acumen and strategic business insight will add important perspective to our board as we evaluate financing and partnering opportunities for optimal growth on our path to commercialization," said David H. Kirn, M.D., president and chief executive officer of Jennerex.

Mr. Cleveland brings over 20 years of experience in strategic corporate transactions and investment banking to the Jennerex board. As executive vice president of corporate development and chief financial officer for Affymax, he manages all business development, strategic planning, financial and legal activities. Prior to Affymax, he served as managing director of the investment banks Integrated Finance, Ltd. and J.P. Morgan Chase and Co. (formerly Hambrecht & Quist), leading healthcare and technology mergers and acquisitions for the firms. Prior to his tenure in investment banking, he was a partner at Cooley Godward LLP. Mr. Cleveland serves as a member of the board of directors of Sangamo BioSciences, Inc.  He holds a J.D. from Northwestern University School of Law and an A.B. from Washington University in St. Louis.

"Paul will be an excellent complement to Jennerex's board of directors, and we welcome him to our team.  His depth of experience will add significant value as we make strategic business decisions going forward," stated Brennan Mulcahy, chairman of the board of Jennerex.

About Jennerex

Jennerex is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594, currently in an international randomized Phase 2 clinical trial for patients with primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the Company's poxviruses in cancer cells. These products not only cause cancer cell lysis thereby killing through replication, they simultaneously shut off the blood supply to tumors, as well as stimulating the body's immune response to the cancer. Jennerex, Inc. is headquartered in San Francisco and has manufacturing and research activities based at the Ottawa Hospital Research Institute in Ottawa, Canada. For more information about Jennerex and the Company's pipeline of three clinical-stage products, please visit www.jennerex.com .


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
2. Jennerex Closes $5 Million First Tranche of Series C Financing
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
5. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
6. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
7. Biotech Industry Showing Resilience Despite Challenging Conditions
8. Global Jatrophaworld Training 2010... Set to Create and Build a Sustainable Biodiesel Industry
9. HealthTalker Adds Industry Expert Collie Turner to Its Executive Team
10. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
11. HealthTalker Programs Leveraging the Power of Word of Mouth Find Huge Success for Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... ... has enhanced the platform to accommodate increasingly complex and sophisticated deployments, resulting ... and more. In addition to these improvements, the latest release brings enhanced ...
(Date:1/11/2017)... , Jan. 11, 2017  Brian Mehling, M.D., ... founder of Blue Horizon International (BHI), will be attending ... Davos from January 17-20, 2017. This ... conference. The theme of this year,s forum ... program,s 400 sessions will address strategies for fostering greater ...
(Date:1/11/2017)... ... January 11, 2017 , ... For many ... when navigating the challenges young businesses face. With the second installment of Quorum’s ... experience of Geoff DiMasi, Founder and Principal of interactive design agency, P’unk Ave. ...
(Date:1/11/2017)... 2017 AnaptysBio, Inc., a clinical-stage biotechnology ... unmet medical needs in inflammation, today announced the ... financial officer.  Mr. Piscitelli will play a key ... overseeing the company,s accounting and SEC reporting functions. ... Dominic to the senior management team at AnaptysBio," ...
Breaking Biology Technology:
(Date:12/15/2016)... AUBURN HILLS, Mich. , Dec. 15, 2016 /PRNewswire/ ... simply unlocking car doors or starting the engine. Continental ... 2017 in Las Vegas . Through ... PASE (Passive Start and Entry) and biometric elements, the ... the field of vehicle personalization and authentication. ...
(Date:12/7/2016)... PUNE, India , December 7, 2016 According to ... NLP, Machine Learning), Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End ... size is estimated to grow from USD 6.72 Billion in 2016 to USD ... Continue Reading ... ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
Breaking Biology News(10 mins):